PT - JOURNAL ARTICLE AU - Ekaterina Makarova AU - Nikolay Menkov AU - Maria Czapaeva AU - Galina Varvarina TI - Interferon inducer in treatment of acute respiratory viral infections in patients with chronic obstructive pulmonary disease DP - 2014 Sep 01 TA - European Respiratory Journal PG - P4689 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/P4689.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/P4689.full SO - Eur Respir J2014 Sep 01; 44 AB - Acute respiratory viral infections (ARVI) are etiological triggers of exacerbations of chronic obstructive pulmonary disease (COPD). Membrane-bound and soluble (s) forms of CD38 antigen are involved in implementation of immune response in viral infections and other pathological conditions.Aim: To study the efficacy of complex medicine with interferon (IFN) inducing activity containing ultralow doses of antibodies against IFN-γ, CD-4 and histamine molecules (ergoferon) in treatment of ARVI in COPD patients and its influence on sCD38 level.Patients and methods: Open comparative clinical trial in 2 groups involving 48 adult COPD patients was performed. The 1st group (25 patients) received ergoferon for ARVI treatment in standard regimen. The 2nd group (23 patients) didn't receive antiviral treatment. All patients obtained also treatment of COPD and necessary symptomatic therapy. Levels of sCD38 were analyzed in serum of patients and 10 healthy donors using ELISA-method.Results: The mean durations of fever and hospitalization were shorter in treatment group than in other group (by 1,7 and 3,8 days respectively). Initial sCD38 serum levels were decreased significantly in both patient groups compared with healthy donors. Significant increase of sCD38 level was observed in the 1st group after the treatment. No changes in sCD38 concentration were measured in the other group. Side effects were not registered during the trial.Conclusion: The use of IFN inducer (ergoferon) for ARVI treatment in COPD patients leads to reduction of disease duration and normalization of impaired profile of sCD38, a marker of cell activation.